ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2022

The Comparison Between IgG4-Related Retroperitoneal Fibrosis and Idiopathic Retroperitoneal Fibrosis

Bon San Koo1, Bin Yoo1, Chang-Keun Lee1, Yong-Gil Kim1, You Jae Kim1, Seokchan Hong2, Wook Jang Seo3 and Kyung joo Ahn4, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Department of rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Seoul Veterans Hospital, Seoul, South Korea, 4KEPCO medical center, Seoul, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IgG4 Related Disease and Retroperitoneal Fibrosing

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

The comparison between IgG4-related retroperitoneal fibrosis and idiopathic retroperitoneal fibrosis

Background/Purpose: The purpose of our study was to identify the ratio of IgG4-related retroperitoneal fibrosis (RPF) which were diagnosed as idiopathic RPF and investigate histological and clinical characteristics of IgG4-related RPF.

Methods: We retrospectively reviewed the medical records of 41 RPF patients in a tertiary care medical center between January 2000 and January 2013. We identified 20 pathologies which were obtained from biopsy or surgery. Immunostaining of IgG4 and histopathologic examination was performed in all surgical pathologies according to 2012 consensus statement on the pathology of IgG4-related disease. Clinical characteristics were also compared between IgG4-related RPF and idiopathic RPF.

Results: In a total 20 RPF cases, more than 30 IgG4 positive plasma cells were identified in 10 cases with dense lymphoplasmacytic infiltrate, storiform fibrosis, or obliterative phlebitis (IgG4 related RPF), but a few (°Â5) IgG4 positive or IgG4 negative cases were also identified in 10 cases (idiopathic RPF). Among 10 IgG4-related RPF, highly suggestive and probable features of IgG4 related RPF in histology were shown in 8 cases and 2 cases, respectively. In comparison between IgG4 related and idiopathic RPF, recurrence rate of IgG4-related RPF (60%) was higher than that of idiopathic RPF (10%) (p=0.032) (figure 1). Initial and 3 month cumulative steroid dosages were not different between two groups.

Conclusion:  We found that IgG4 related RPF according to 2012 consensus statement on the pathology of IgG4-related disease was 50% of the patients who had been diagnosed as idiopathic RPF in the past. We suggested that more aggressive therapy might be considered in IgG4-related RPF to reduce recurrence rate initially.

Figure 1. The recurrence-free rate of IgG4-related and idiopathic retroperitoneal fibrosis


Disclosure:

B. S. Koo,
None;

B. Yoo,
None;

C. K. Lee,
None;

Y. G. Kim,
None;

Y. J. Kim,
None;

S. Hong,
None;

W. J. Seo,
None;

K. J. Ahn,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-comparison-between-igg4-related-retroperitoneal-fibrosis-and-idiopathic-retroperitoneal-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology